🔴 Sellas Life Sciences is trading 5.48% down today on Phase 3 REGAL AML trial delay concerns

Sellas Life Sciences is trading at $10.70 (-5.48%) as shares extend a pullback driven by investor uncertainty regarding clinical trial timelines.

• Market participants are expressing concern over a possible delay in the Phase 3 REGAL trial data release for Acute Myeloid Leukemia (AML), with traders waiting for the final event threshold and topline readout.
• The downward movement follows a recent biotech-sector rally, suggesting profit-taking as the focus shifts to company-specific catalysts.
• While broader biotech sentiment remains mixed, the specific timing of the REGAL trial results appears to be the primary driver of today's price action.